10 hrs ago
Sensitization of human cancer cells to gemcitabine by the Chk1...
Chk1 inhibitors have emerged as promising anticancer therapeutic agents particularly when combined with antimetabolites such as gemcitabine, cytarabine or hydroxyurea.
High-dose cytarabine improves outcome in patients with Aml in Eortc-Gimema Aml-12 Trial
Results of the EORTC and GIMEMA AML-12 Trial appearing in the Journal of Clinical Oncology show that high-dose cytarabine in induction treatment improves outcome of adult patients with acute myeloid leukemia .
Celator Pharmaceuticals, Inc. Announces Positive Data And Safety...
Celator Pharmaceuticals, Inc. , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the independent Data and Safety Monitoring Board for the Company's Phase 3 clinical study comparing CPX-351 Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen as first-line ... (more)
Cell Therapeutics Announces Presentation of Interim Results from...
Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome at ASH Annual Meeting -- Interim Results of Tosedostat in Combination with Chemotherapy or Hypomethylating Agents in First-line Demonstrate 54 Percent Complete Response Rate and 12-Month ... (more)
Bone Marrow Transplantation
To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century
Correspondence: Dr D Weisdorf, Division of Hematology-Oncology and Transplantation, Department of Medicine, University of Minnesota, 14-142 PWB, 516 Delaware, Street SE, Minneapolis, MN 55455, USA.